Sophie Marolleau

  • Sophie Marolleau
Fil d'ariane
    • PhD Student

    Publications HAL

    Pré-publication, Document de travail (1 document)
    • Anne Rodallec, Randy Lee, Jingming Cao, Sophie Marolleau, Julien Nicolas, et al.. Model-driven scheduling of a novel anti-cancer polymer prodrug administered subcutaneously. 2025. ⟨hal-04937053⟩
    Poster (5 documents)
    • J. Ciccolini, M. Hamimed, S. Marolleau, C. Perez, S. Benzekry, et al.. 1380P PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial. ESMO Congress 2024, Sep 2024, Barcelone, Spain. Annals of Oncology, 35, pp.S866-S867, 2024, ⟨10.1016/j.annonc.2024.08.1435⟩. ⟨hal-04830263⟩
    • Anne Rodallec, Randy Lee, Sophie Marolleau, Sébastien Benzekry, Julien Nicolas. PK/PD modelling to advance the preclinical development of a novel polymer prodrug in oncology. CRS 2024 Annual Meeting and Expo : integrating Delivery Science across disciplines, Jul 2024, Bologna, Italy. ⟨hal-04719303⟩
    • Sophie Marolleau, Alice Mogenet, Clara Boeri, Mourad Hamimed, Joseph Ciccolini, et al.. Standard atezolizumab leads to severe overexposure in real-world patients with lung cancer: How far could we go in extending dosing intervals and saving money?. 2024 ASCO Annual Meeting, May 2024, Chicago, United States. Journal of clinical Oncology, 42 (16_suppl), pp.3085-3085, 2024, ⟨10.1200/JCO.2024.42.16_suppl.3085⟩. ⟨hal-04830289⟩
    • Sophie Marolleau, Alice Mogenet, Mourad Hamimed, Clara Boeri, Laurent Greillier, et al.. Abstract 7162: Killing a fly with a sledgehammer: standard flat-dosing administration of Atezolizumab leads to marked overexposure in real-world lung cancer patients. AACR Annual Meeting, Apr 2024, San Diego, United States. Cancer Research, 84 (6_Supplement), pp.7162-7162, 2024, ⟨10.1158/1538-7445.AM2024-7162⟩. ⟨hal-04830273⟩
    • Anne Rodallec, Randy Lee, Sophie Marolleau, Sébastien Benzekry, Julien Nicolas. Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors. ESCDD, May 2022, Egmond aan Zee, Netherlands. 16, 2020, ⟨10.1371/journal.pcbi.1007178⟩. ⟨hal-04726607⟩
    Article dans une revue (2 documents)
    • Sophie Marolleau, Alice Mogenet, Clara Boeri, Mourad Hamimed, Joseph Ciccolini, et al.. Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients. CPT: Pharmacometrics and Systems Pharmacology, 2023, 12 (11), pp.1795-1803. ⟨10.1002/psp4.13063⟩. ⟨hal-04352276⟩
    • Sarah Baklouti, S. Marolleau, P. Chavanet, E. Bonnet, Didier Concordet, et al.. Why Is It Desirable To Do the External Evaluation of a Population Pharmacokinetic Model?. Antimicrobial Agents and Chemotherapy, 2022, 66 (1), ⟨10.1128/AAC.01493-21⟩. ⟨hal-03578727⟩

    Short CV:

    Sophie Marolleau (born 08.04.1976, France) is a PhD Student in Pharmacometrics at the University of Poitiers, School of Medicine and Pharmacy, in unit UMR 1070 « Pharmacology of Antimicrobial Agents ». Recruited in 2023, she is currently working on Deca-P and STARs-TAP. She is mainly involved in modeling of TAP activity and resistance plasmid transfer dynamics.

    Her academic training in pharmaceutical sciences (PharmD in 2023) provided her with a solid knowledge in pharmacology and pharmacometrics. She is familiar with modeling in population pharmacokinetics and PK/PD, and she has developed during her Master’s degree internship in COMPO team at CRCM (Centre de Recherche en Cancerologie de Marseille) strong skills about nanomedicines and immunotherapy.

    Project involvement:

    Deca-P and STARs-TAP

    Main recent publications:

    Find me on…

     

    • Find us on

    INSERM U1070

    UFR de Médecine et Pharmacie - Université de Poitiers - Pôle Biologie Santé - Bâtiment B36
    1 rue Georges Bonnet
    86022 POITIERS Cedex, France

    (33) (0)5 49 45 49 69
    (33) (0)5 49 45 43 78

    Envoyer un mail